

Exploring the Role of Oxidative Stress-Related Molecular Biomarkers in Cardiovascular Disease Progression and Therapeutic Modulations: A Systematic Analysis

Jannat Ikram¹ | Sadia Akram¹

¹School of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan

*Correspondence: Jannat Ikram (psacca119@gmail.com)

Citation: Ikram J, Akram S. Exploring the Role of Oxidative Stress-Related Molecular Biomarkers in Cardiovascular Disease Progression and Therapeutic Modulations. *J Biomol Pathog Ther.* 2026;2(1):35-42.

Received: 01 January, 2026

Revised: 20 February, 2026

Accepted: 28 February, 2026

Published: 10 March, 2026

ABSTRACT

Background: Oxidative stress plays a significant role in the pathogenesis of cardiovascular diseases (CVD), endothelial dysfunction and hypertension. The purpose of this study was to synthesize the evidence on the role of critical oxidative stress biomarkers in the etiology of associated diseases to determine their therapeutic potential. **Methods:** PRISMA 2020 guidelines were followed to conduct this study. Reported literature was searched using PubMed, Scopus, Web of Science, and Google Scholar from 2014 to 2025. Those studies that investigated certain biomarkers of oxidative stress (ROS, superoxide dismutase (SOD), glutathione peroxidase (GPx), malondialdehyde (MDA)) in the pathophysiology of CVD, endothelial dysfunction and hypertension were included. Non-English articles and studies without mechanistic or therapeutic outcomes were excluded. The risk of bias was evaluated with the help of Newcastle-Ottawa Scale, Cochrane risk of bias 2, and SYRCLE tool, and the certainty of evidence was measured with the help of the GRADE approach. **Results:** Findings of twelve studies were included in this review, which demonstrated that high level of mitochondrial ROS and MDA, and low activity of SOD and GPx were major contributor to endothelial dysfunction, hypertension and CVD. Melatonin, resveratrol, Nicotinamide Adenine Dinucleotide precursors and mitochondrial-targeted antioxidants proved to be effective therapeutic agents. The risks of bias among included studies ranged from low to high, and the confidence of the evidence ranged from low to moderate. **Conclusion:** Oxidative stress biomarkers are critical in cardiovascular disease pathogenesis and hold significant therapeutic potential. Further extensive trials are needed to validate these indicators as diagnostic tools and convert targeted antioxidant therapy into successful precision medicine.

Keywords: Oxidative Stress, Reactive Oxygen Intermediates, Superoxide Dismutase, Malondialdehyde, Endothelial, Hypertension, Cardiovascular Disease, Antioxidant Effects

Oxidative stress is primarily involved in variety of chronic conditions including endothelial dysfunction, cardiovascular diseases (CVD), and hypertension ¹⁻³. It is characterized by imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense mechanisms ⁴. The presence of ROS, antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GPx), and lipids peroxidation products such as malondialdehyde (MDA) are the direct measures to determine oxidative stress ⁵. The abnormal levels of these biomarkers were associated with cellular injury, inflammation, and development of chronic conditions by disrupting key functions, such as nitric oxide bioavailability and mitochondrial integrity ⁶.

Precise role of certain oxidative stress biomarkers, including ROS, SOD, and MDA, and their association with stages in cardiovascular diseases remained a critical area of research ⁷. It is essential to understand the mechanistic link that how mitochondrial ROS (mtROS) is responsible for endothelial dysfunction or whether the levels of MDA are associated with the onset of acute coronary events ⁸. Moreover, identifying reliable biomarkers offer a dual promise; it not only enhanced early diagnostic and prognostic precision, but also the possibility to focus on specific therapeutic targets, paving the way for personalized antioxidant strategies ⁹. Innovative hydrogel-drug delivery systems had also been explored to potentially mitigate oxidative stress-related damage in cardiovascular and metabolic contexts ¹⁰.

Despite the growing research on oxidative stress in cardiovascular diseases, the fragmented evidence based on different study designs, disease settings, and on different biomarkers resulted in inconsistent findings. A logical synthesis was needed to gather and evaluate the findings on the diagnostic, prognostic, and therapeutic relevance of the critical oxidative stress markers. This systematic review was intended to determine whether oxidative stress biomarkers, including ROS, antioxidant enzymes (SOD, GPx), and lipid peroxidation products (MDA) played a role in the development of diseases, specifically in oxidative stress-based endothelial dysfunction, CVD, and hypertension tress. It also aimed to determine the clinical relevance of regulating these biomarkers in progression of diseases.

Methodology

PRISMA 2020 guidelines were followed for the synthesis of this systematic review ¹¹.

Databases and Search Strings Used: The authors selected research from 2014 to September 2025 by using databases PubMed, Scopus, Web of Science, and Cochrane Library. A combination of MeSH and free-text keywords related to oxidative stress biomarkers, diseases, and therapeutic targeting were used such as "oxidative stress", "reactive oxygen species", "lipid peroxidation", "antioxidant enzyme", "cardiovascular disease", "endothelial dysfunction", "hypertension", "superoxide dismutase", "glutathione peroxidase", "malondialdehyde", and "therapeutic target". Literature search was further refined by the use of Boolean operators.

Inclusion and Exclusion Criteria: For a study to be included in this review, it should be original research article, such as experimental, observational, or clinical investigations, examining the mechanistic role or therapeutic potential of specific oxidative stress biomarker(s) (ROS, SOD, GPx, MDA) in the pathogenesis of a defined chronic disease (endothelial dysfunction, CVD, and hypertension). Only articles published in English were considered. Studies were excluded if they were reviews and editorials, or if they did not focus on a specific disease, explored oxidative stress biomarkers without a direct link to disease mechanisms or treatment.

Study Selection: The title and abstract of studies were reviewed independently by two researchers on the basis of predefined inclusion criteria. The reviewers settled their selection differences either through group agreement or expert consultation.

Data Extraction: Two independent reviewers performed data extraction, which included information about study design, disease context, key biomarkers analyzed, main findings and therapeutic implications. The reviewers either achieved consensus or consulted a third person to settle any differences. When necessary, corresponding authors were contacted for missing or clarifying data.

Primary Outcome and Quality Assessment: The primary outcome of this study was to evaluate the role of critical oxidative stress biomarkers (ROS, SOD, GPx, MDA) in the progression of associated diseases, specifically endothelial dysfunction, CVD, and hypertension, and to assess their potential as therapeutic targets. Risk of bias among the included studies were assessed through the SYRCLE risk of bias (RoB) for preclinical studies, Cochrane RoB 2 for randomized control trial, a combined tool for the hybrid study, and the Newcastle-Ottawa Scale (NOS) for observational studies ¹²⁻¹⁴. GRADE criteria were used to evaluate the certainty of evidence.

Results

The study demonstrated the role of oxidative stress biomarkers (ROS, SOD, GPX, MDA) in the progression of endothelial dysfunction, CVD, and hypertension. Among the searched electronic databases and other sources, 220 research articles were initially selected. The number was reduced to 180 records after removing the duplicates. Title and abstract screening further eliminated 26 studies. From the remaining 74 articles, 30 were removed due to unavailability of access to the full-texts. Further 44 articles were screened, and 32 were eliminated due to a lack of stratified data and studies including animals, in vitro findings, reviews, case reports, or languages other than English. Ultimately, twelve studies that passed the inclusion criteria were included in this systematic review. The PRISMA flow diagram presented in Figure 1 illustrates the selection process. The characteristics of the included studies including the disease studied, key biomarkers analyzed, study findings and therapeutic implications were summarized in Table 1.




Figure 1: Study Selection Process following PRISMA 2020 guidelines

Table 1: Systematic Review Table Representing Characteristics and Key Findings of Studies

Author & Year (Country)	Disease Context	Key Biomarkers Investigated	Study Design & Model(s)	Sample Size / Population Characteristics	Key Findings	Therapeutic Implications
Li et al., 2021 ¹⁵ (China)	Endothelial dysfunction /Atherosclerosis	Mitochondrial ROS, SOD, GPX, GSH	Experimental Study	Cell Line (HUVECs)	Melatonin reduced mitochondrial ROS, increased SOD, GPX, and GSH activity.	Melatonin enhances antioxidant defense and reduces ROS to protect endothelial cells.

Cao et al., 2022 ¹⁶ (China)	Endothelial dysfunction /Atherosclerosis	Mitochondrial ROS, SOD2 activity	Experimental Study	Mice models (n not specified)	SIRT3 knockdown elevate ROS. NAD ⁺ supplementation reduced mitochondrial ROS and increased SOD2 activity.	NAD ⁺ precursors reduce mitochondrial ROS and improve endothelial function via SIRT3 and antioxidant upregulation.
Zhou et al., 2014 ¹⁷ (China)	Endothelial dysfunction / Atherosclerosis	Mitochondrial ROS, SOD2 activity, GSH-Px, IDH2	Experimental Study	Cell Line (HUVECs)	Resveratrol decreased mitochondrial ROS, increased SOD2, GSH-Px, and IDH2 activity.	Resveratrol boosts mitochondrial antioxidant enzyme activity and reduces ROS via SIRT3 activation.
Murray et al., 2023 ¹⁸ (United States)	Endothelial dysfunction	Mitochondrial ROS	Randomized Control Trial with Ancillary Analysis	Plasma samples from 19 subjects; Cell Line (HAECs)	MitoQ reduced circulating oxLDL and mitochondrial ROS in HAECs. Lower oxLDL correlated with improved NO production and reduced ROS.	Mitochondrial-targeted antioxidants reduce lipid peroxidation and mitochondrial ROS, improving vascular function.
He et al., 2019 ¹⁹ (China)	Hypertension	SOD2 activity, mtROS	Clinical-Experimental Hybrid Study	20 hypertensive patients, 20 controls; mouse studies (n=6–8/group)	Hypertension reduces SIRT3, increases SOD2 acetylation, elevates mtROS, impairs EPC reendothelialization.	Enhancing SIRT3/SOD2 signaling may improve endothelial repair in hypertension.
Dikalov a et al., 2020 ²⁰ (United States)	Hypertension	SOD2 acetylation, Vascular ROS	Comparative experimental laboratory study	Mouse models(n=4–8/group); Human tissue from hypertensive & normotensive subjects	Mice models and human hypertensives showed SIRT3 depletion increases SOD2 acetylation, oxidative stress, inflammation, and hypertension.	SIRT3 activation may be a therapeutic target to reduce oxidative stress, inflammation, and hypertension.
García-Sánchez et al., 2023 ²¹ (Mexico)	Hypertension , Obesity	SOD and catalase activity	Cross-sectional study	175 subjects	↓ SOD & catalase activity in hypertension.	Targeting mitochondrial function and antioxidant capacity may help manage obesity-related hypertension.
Huang et al., 2022 ²² (China)	Hypertension	SOD activity	Cross-sectional study	1,630 adults	At SOD ≤58 IU/mL, ↓ SOD associated with ↑ diastolic hypertension risk.	Increasing SOD levels within a certain range may reduce diastolic hypertension risk in the elderly.
Moronkeji et al., 2024 ²³ (Nigeria)	Cardiovascular Diseases	Malondialdehyde	Case-Control Study	121 participants	Significantly elevated levels of MDA in CVD patients.	Biomarkers may aid in early diagnosis and monitoring. Antioxidant interventions could mitigate oxidative damage.
Amioka et al., 2019 ²⁴ (Japan)	Acute Coronary Syndrome	Malondialdehyde - modified LDL	Retrospective cohort study	370 patients	↑ MDA-LDL levels >161 U/L predict major adverse cardiac events, especially revascularization and linked to worse prognosis.	MDA-LDL may serve as a prognostic biomarker for guiding intensive lipid and antioxidant therapy.
Nagusu ndaram et al.,	Acute Myocardial Infarction	Malondialdehyde	Cross-sectional case-control	86 participants (43 AMI patients, 43	Serum MDA levels were significantly higher in AMI	MDA may serve as an adjuvant diagnostic/prognostic

2025 ²⁵ (India)			study	healthy controls)	patients (21.8 ± 4.5 ng/ml) vs. controls (4.4 ± 1.4 ng/ml). MDA correlated with oxidative stress.	biomarker. Antioxidant therapy may help reduce oxidative injury in AMI.
Arif et al., 2019 ²⁶ (Iraq)	Coronary artery disease (post-surgical)	Malondialdehyde	Longitudinal case-control study	50 patients (open-heart surgery), 30 healthy controls	Elevated MDA levels positively correlated with total cholesterol, indicating surgery-induced oxidative stress and reperfusion injury.	Monitoring MDA may help assess reperfusion injury. Antioxidant strategies during/after surgery could mitigate oxidative stress.

ox-LDL = Oxidized Low-Density Lipoprotein; HUVECs = Human Umbilical Vein Endothelial Cells; ROS = Reactive Oxygen Species; SOD = Superoxide Dismutase; GPX = Glutathione Peroxidase; GSH = Glutathione; MitoSOX = Mitochondrial Superoxide Indicator; mBMECs = Mouse Brain Microvascular Endothelial Cells; SIRT3 = Sirtuin 3; NAD⁺ = Nicotinamide Adenine Dinucleotide; IDH2 = Isocitrate Dehydrogenase 2; GSH-Px = Glutathione Peroxidase; t-BHP = tert-butyl hydroperoxide; MitoSOX = Mitochondrial Superoxide; MitoQ = Mitochondria-targeted Antioxidant; HAECs = Human Aortic Endothelial Cells; EPCs = Endothelial Progenitor Cells; mtROS = Mitochondrial Reactive Oxygen Species; AMI = Acute Myocardial Infarction; MDA = Malondialdehyde; CVD = Cardiovascular Diseases; MI = Myocardial Infarction; 8-OHdG = 8-hydroxy-2'-deoxyguanosine; hOGG1 = 8-oxoguanine glycosylase; TNF- α = Tumor Necrosis Factor-alpha; IL-6 = Interleukin-6

The synthesis of twelve studies revealed that dysregulated oxidative stress biomarkers are key contributors to disease progression. In particular, the presence of high levels of mtROS and MDA, as well as the reduction in the activity of antioxidant enzymes (SOD2 and GPx) were directly related to the pathophysiology of endothelial malfunctioning, atherosclerosis, hypertension, and acute cardiovascular events. Moreover, the therapeutic interventions that had been shown to target these pathways, such as melatonin, resveratrol, Nicotinamide Adenine Dinucleotide (NAD⁺) precursors and the mitochondrial-targeted antioxidant, modulated these biomarkers to reduce oxidative damage in cellular and animal models, and in preclinical human trials.

Study-specific tools for risk of bias evaluation such as, SYRCLE for preclinical studies, Cochrane RoB 2 for randomized control trial, a combined tool for the hybrid study, and the NOS for observational studies were used (Table 2).

Table 2: Risk of bias among Included Studies

Risk of Bias for In Vitro & Preclinical Experimental Studies using SYRCLE's RoB Tool							
Author & Year	Selection Bias	Performance Bias	Detection Bias	Attrition Bias	Reporting Bias	Other Bias	Overall Risk
Li et al., 2021 ¹⁵	Low (Cell line source stated)	Unclear (Blinding of investigators not stated)	Unclear (Blinding of outcome assessment not stated)	Low (Full data reported)	Low (All methods reported)	Low	Moderate
Cao et al., 2022 ¹⁶	Low (Animal/genotype details clear)	Low (Randomization to groups mentioned)	Unclear (Blinding of assessors not stated for all outcomes)	Low (No attrition mentioned)	Low (Methods comprehensive)	Low	Low
Zhou et al., 2014 ¹⁷	Low (Cell isolation & culture detailed)	Unclear (No blinding mentioned)	Unclear (No blinding of analysis mentioned)	Low (Full data shown)	Low (Protocols detailed)	Low	Moderate
Dikalov a et al., 2020 ²⁰	Low (Animal models well-described, randomization used)	Low (Randomized group allocation)	Unclear (Blinding not explicitly stated for all measures)	Low	Low (All outcomes reported)	Low	Moderate
Risk of Bias for Randomized Controlled Trial using Cochrane RoB-2 Tool							
Author & Year	Randomization Process	Deviations from Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result		Overall Risk
Murra y et al., 2023 ¹⁸	Low (Randomized, double-blind, crossover, counter-balanced)	Low (Double-blind, placebo-controlled)	Low (19/20 subjects analyzed, reasons provided)	Low (Objective lab measures, standardized protocols)	Low (Pre-specified outcomes, trial registered)		Low
Risk of Bias for Clinical-Experimental Hybrid Study using Hybrid Tool							
Author & Year	Human Subject Selection	Exposure Bias	Animal Study Bias	Measurement Bias	Reporting Bias		Overall Risk
He et	Unclear	High	Unclear (Animal	Unclear	Low		Moderate-

al., 2019 ¹⁹	(Convenience sampling of patients/controls)	(No blinding in human observational part)	procedures described, blinding not stated)	(Some assays blinded, others not specified)	(Complete Data provided)	High
Table 5: Risk of Bias for Observational Studies using Newcastle-Ottawa Scale (NOS) Tool						
Author & Year	Selection Bias		Comparability Bias		Outcome/Exposure (Risk of Bias)	Overall Risk of Bias
Cross-Sectional Studies						
García-Sánchez et al., 2023 ²¹	Medium (Defined cases, community-based, but recruitment details limited)		High (Matched for some factors, but many confounders present)		Medium (Validated assays, but single measurement)	Moderate-High
Huang et al., 2022 ²²	Low (Large national cohort, clear inclusion/exclusion)		Low (Adjusted for multiple key confounders in models)		Low (Standardized BP measurement, assay used)	Low
Nagusundaram et al., 2025 ²⁵	High (Convenience sampling, matched controls)		High (No adjustment for confounders like age/sex beyond matching)		Medium (Standard lab assay)	High
Case-Control Study						
Moronkeji et al., 2024 ²³	High (Cases from hospital, controls from community; source not identical)		High (Limited adjustment for confounders reported)		Medium (Blinded lab analysis likely, but methods brief)	High
Retrospective Cohort Study						
Amioka et al., 2019 ²⁴	Medium (Consecutive ACS patients, clear criteria)		Low (Multivariable adjustment for key prognostic factors)		Medium (Blinded outcome assessment, objective endpoint)	Moderate
Longitudinal Case-Control Study						
Arif et al., 2019 ²⁶	Medium (Clear patient group, healthy controls)		High (No adjustment for confounders; design is within-subject comparison)		Medium (Repeated measures, assay described)	Moderate-High

Orange color represents “Moderate-High” risk of bias; Yellow color represents “Moderate” risk of bias; Green color represents “Low” risk of bias; Red color represents “High” risk of bias

Discussion

The synthesized evidence from the twelve studies was investigated for oxidative stress biomarkers in various disease pathologies including endothelial dysfunction, CVD, and hypertension. The findings consistently demonstrated the presence of high levels of mtROS and MDA, as well as suppressed activity of antioxidant enzymes such as SOD2 were strongly associated with disease progression²⁷⁻³⁰. The mtROS acted as a mediator in endothelial dysfunction and atherosclerosis, whereas in acute coronary syndrome and myocardial infarction, MDA had become one of the main prognostic factors³¹. Studies on cardiovascular disease have also highlighted the importance of biochemical and functional markers in assessing disease severity and recovery outcomes³². Melatonin, resveratrol, NAD⁺ precursors, and mitochondrial-targeted antioxidants like mitochondria-targeted coenzyme Q were effective therapeutic interventions to restore the balance of these biomarkers and improving functional outcomes³³⁻³⁵.

Overall, the results suggested that oxidative stress biomarkers including mtROS, SOD2 activity, and MDA should be included in stratified risk assessment of CVD and hypertension during clinical practice. The analyzed articles established a clear mechanistic link between oxidative biomolecular imbalances to tissue injury³⁶. Experimental studies have demonstrated that oxidative stress and antioxidant imbalance play a central role in cellular injury and disease progression across multiple organ systems^{30,33,37}. In endothelial dysfunction, excess mtROS inactivated nitric oxide promoted a pro-inflammatory state, directly contributing to atherosclerotic plaque development³⁸. Mitochondrial SOD2 acetylation and inactivation led to sustained oxidative stress in hypertension which hindered vascular repair³⁹.

In acute cardiovascular events, lipid peroxidation product MDA not only served as the damage marker but also as a mediator of further oxidative damage and inflammation, increasing the reperfusion injury and poor prognosis after myocardial infarction⁴⁰⁻⁴². These findings were consistent with the existing literature emphasizing oxidative stress as a broad-spectrum pathology. The recurrent involvement of SIRT3 in the regulation of mitochondrial antioxidant defenses (SOD2) in various studies supported its new emerging status as a key regulatory node⁴³. Similarly, the association of adverse cardiac events and MDA also proved its application with clinical biomarkers⁴⁴. However, the difference in the magnitude of effect and optimal cut-off values of biomarkers like SOD reflected the impact of the population peculiarities and disease progression⁴⁵.

This study had several limitations. The heterogeneity in the study designs of included studies, model systems and patient populations limited the direct comparability of the findings. The assessment of risk of bias indicated some concerns especially related to cases with observational and experimental studies which included lack of clarity regarding blinding, selection bias, and confounding factors. The preclinical models were based on many cell lines and animal models, and could not be directly translated to human pathophysiology. Moreover, unpublished or non-English studies were excluded, introducing a publication bias. Further studies are required to conduct large-scale, longitudinal cohort studies that will determine the causal timelines and reference ranges. Rigorous, randomized controlled trials in combination with mitochondrion-specific antioxidant therapies, should be undertaken in order to convert these mechanistic effects into definitive clinical benefits. The policy-makers should promote the standardization of these oxidative stress biomarker assays to facilitate comparison across studies.

Conclusion

This review concluded that certain oxidative stress biomarkers (ROS, SOD, GPx, and MDA) played a crucial role in the pathogenesis of endothelial dysfunction, CVD, and hypertension, and could be exploited as therapeutic targets. However, the evidences were considered weak due to the methodological heterogeneity among included studies. Thus, large-scale clinical trials should be conducted to confirm the potential of these biomarkers and to translate targeted therapies into precision medicine.

Acknowledgement

None

Conflict of Interest

None

Grant Support & Funding Source

None

Use of Artificial Intelligence

The corresponding author declared that no artificial intelligence or AI-assisted tools were used in this manuscript.

Authors' Contribution

SF conceived the idea and participated in study design, data collection and assembly, critical revision of manuscript and statistical analysis. JI participated in data collection and assembly, data analysis and interpretation. SA participated in writing manuscript and statistical analysis; PD participated in critical revision of the manuscript. All authors approved the final manuscript and agree to be accountable for its content.

References

1. Donia T, Khamis A. Management of oxidative stress and inflammation in cardiovascular diseases: mechanisms and challenges. *Environ Sci Pollut Res*. 2021;28(26):34121-53. <https://doi.org/10.1007/s11356-021-14109-9>
2. Scioli MG, Storti G, D'Amico F, Rodríguez Guzmán R, Centofanti F, Doldo E, et al. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. *J Clin Med*. 2020;9(6):1995. <https://doi.org/10.3390/jcm9061995>
3. Higashi Y. Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease. *Antioxidants*. 2022;11(10):1958. <https://doi.org/10.3390/antiox11101958>
4. Sies H, Belousov VV, Chandel NS, Davies MJ, Jones DP, Mann GE, et al. Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology. *Nat Rev Mol Cell Biol*. 2022;23(7):499-515. <https://doi.org/10.1038/s41580-022-00456-z>
5. Gianazza E, Brioschi M, Martinez Fernandez A, Casalnuovo F, Altomare A, Aldini G, et al. Lipid peroxidation in atherosclerotic cardiovascular diseases. *Antioxid Redox Signal*. 2021;34(1):49-98. <https://doi.org/10.1089/ars.2019.7955>
6. García-Sánchez A, Miranda-Díaz AG, Cardona-Muñoz EG. The role of oxidative stress in physiopathology and pharmacological treatment with pro-and antioxidant properties in chronic diseases. *Oxid Med Cell Longev*. 2020;2020(1):2082145. <https://doi.org/10.1155/2020/2082145>
7. Reddy VP. Oxidative stress in health and disease. *Biomedicines*. 2023;11(11):2925. <https://doi.org/10.3390/biomedicines11112925>
8. Panda P, Verma HK, Lakkakula S, Merchant N, Kadir F, Rahman S, et al. Biomarkers of oxidative stress tethered to cardiovascular diseases. *Oxid Med Cell Longev*. 2022;2022(1):9154295. <https://doi.org/10.1155/2022/9154295>

9. Ait Tayeb AEK, Poinsignon V, Chappell K, Bouligand J, Becquemont L, Verstuyft C. Major depressive disorder and oxidative stress: a review of peripheral and genetic biomarkers according to clinical characteristics and disease stages. *Antioxidants*. 2023;12(4):942. <https://doi.org/10.3390/antiox12040942>
10. Sami AJ, Khalid M, Nasar S, Mangat HA, Butt YN. Sustained release of ibuprofen by a novel formulated hydrogel containing graphene oxide. *J Mol Pharm Org Process Res*. 2018;6:143. <https://doi.org/10.4172/2329-9053.1000143>
11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *bmj*. 2021;372. <https://doi.org/10.1136/bmj.n71>
12. Hooijmans CR, Rovers MM, De Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol*. 2014;14(1):43. <https://doi.org/10.1186/1471-2288-14-43>
13. Carra MC, Romandini P, Romandini M. Risk of Bias Evaluation of Cross-Sectional Studies: Adaptation of the Newcastle-Ottawa Scale. *J Periodontal Res*. 2025. <https://doi.org/10.1111/jre.13405>
14. Moore TH, Higgins JP, Dwan K. Ten tips for successful assessment of risk of bias in randomized trials using the RoB 2 tool: Early lessons from Cochrane. *Cochrane Evid Synth Methods*. 2023;1(10):e12031. <https://doi.org/10.1002/cesm.12031>
15. Li P, Xie C, Zhong J, Guo Z, Guo K, Tu Q. Melatonin attenuates ox-LDL-Induced endothelial dysfunction by reducing ER stress and inhibiting JNK/Mff signaling. *Oxid Med Cell Longev*. 2021;2021(1):5589612. <https://doi.org/10.1155/2021/5589612>
16. Cao X, Wu Y, Hong H, Tian XY. Sirtuin 3 dependent and independent effects of NAD⁺ to suppress vascular inflammation and improve endothelial function in mice. *Antioxidants*. 2022;11(4):706. <https://doi.org/10.3390/antiox11040706>
17. Zhou X, Chen M, Zeng X, Yang J, Deng H, Yi L, et al. Resveratrol regulates mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in human vascular endothelial cells. *Cell Death Dis*. 2014;5(12):e1576-e. <https://doi.org/10.1038/cddis.2014.530>
18. Murray KO, Ludwig KR, Darvish S, Coppock ME, Seals DR, Rossman MJ. Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress. *Am J Physiol Heart Circ Physiol*. 2023;325(1):H187-H94. <https://doi.org/10.1152/ajpheart.00270.2023>
19. He J, Liu X, Su C, Wu F, Sun J, Zhang J, et al. Inhibition of mitochondrial oxidative damage improves reendothelialization capacity of endothelial progenitor cells via SIRT3 (Sirtuin 3)-enhanced SOD2 (superoxide dismutase 2) deacetylation in hypertension. *Arterioscler Thromb Vasc Biol*. 2019;39(8):1682-98. <https://doi.org/10.1161/ATVBAHA.119.312613>
20. Dikalova AE, Pandey A, Xiao L, Arslanbaeva L, Sidorova T, Lopez MG, et al. Mitochondrial deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress. *Circ Res*. 2020;126(4):439-52. <https://doi.org/10.1161/CIRCRESAHA.119.315767>
21. García-Sánchez A, Gómez-Hermosillo L, Casillas-Moreno J, Pacheco-Moisés F, Campos-Bayardo TI, Román-Rojas D, et al. Prevalence of hypertension and obesity: profile of mitochondrial function and markers of inflammation and oxidative stress. *Antioxidants*. 2023;12(1):165. <https://doi.org/10.3390/antiox12010165>
22. Huang Y, Wei L, Hong C, Qi-Fan L, Ju-Xiang L, Jin-Zhu H. The L-shaped association between superoxide dismutase levels and blood pressure in older Chinese adults: community-based, cross-sectional study. *J Geriatr Cardiol*. 2022;19(1):71. <https://doi.org/10.11909/j.issn.1671-5411.2022.01.002>
23. Moronkeji A, Olaniyan M. Evaluation of 8-hydroxy-2'-deoxyguanosine, interleukin-8 and malondialdehyde among patients with cardiovascular diseases in Ibadan, Oyo State. *Sokoto J Med Lab Sci*. 2024;9(2):160-9. <https://doi.org/10.11909/j.issn.1671-5411.2022.01.002>
24. Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueda M, et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *J Cardiol*. 2019;74(3):258-66. <https://doi.org/10.1016/j.jjcc.2019.02.012>
25. Nagasundaram M, Singh YR, Singh TSD, Shaini L, Laishram N. Study Of Serum Malondialdehyde Level In Patients with Acute Myocardial Infarction (AMI). *Int J Acad Med Pharm*. 2025;7(3):625-9. <https://doi.org/10.47009/jamp.2025.7.3.120>
26. Arif MA, Ahmeid MS, Allaw SA. Malondialdehyde level in the patients subjected to open heart surgery in association with lipid profile. *Mustansiriyah Med J*. 2019;18(1):30-5. https://doi.org/10.4103/MJ.MJ_34_18
27. Minjares M, Wu W, Wang J-M. Oxidative stress and microRNAs in endothelial cells under metabolic disorders. *Cells*. 2023;12(9):1341. <https://doi.org/10.3390/cells12091341>
28. Radovanović J, Banjac K, Obradović MM, Isenović ER. Antioxidant enzymes and vascular diseases. *Explor Med*. 2021;2(6):544-55. <https://doi.org/10.37349/emed.2021.00070>
29. Qazi N, Memon S, Memon F, Goswami P, Sirhandi BR, Goswami B. Antioxidant and hepato-protective effects of ginger in comparison with atorvastatin in hyperlipidemic albino mice. *JMMC*. 2024 Oct 6;15(1):21-26. <https://doi.org/10.62118/jmmc.v15i1.464>
30. Bano U, Memon S, Shahani MY, Shaikh P, Gul S. Epigenetic effects of in utero bisphenol A administration: Diabetogenic and atherogenic changes in mice offspring. *Iran J Basic Med Sci*. 2019 May;22(5):521-528. <https://doi.org/10.22038/ijbms.2019.29909.7357>
31. de Paula da Silva MV, Villar-Delfino PH, Nogueira-Machado JA, Volpe CM. IL-6, IL-1 β , and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome. *Recent Adv Inflamm Allergy Drug Discov*. 2021;15(2):71-9. <https://doi.org/10.2174/2772270816666220211091231>
32. Brohi GH, Memon SR, Shahani MY, Memon S, Bano U. Acute myocardial infarction: short-term effect of successful aspiration in primary stenting on patients with acute myocardial infarction. *Prof Med J*. 2018;25(8):1223-8. <https://doi.org/10.29309/TPMJ/2018.25.08.44>

33. Shahani SB, Shaikh P, Memon SG, Memon S. Possible prevention of reactive oxygen species induced human trabecular meshwork cell damage by resveratrol and ascorbic acid. *Prof Med J*. 2019 May 31;26(07):1036-1041. <https://doi.org/10.29309/TPMJ/2019.26.07.3229>
34. Liu Y, Huang Y, Xu C, An P, Luo Y, Jiao L, et al. Mitochondrial dysfunction and therapeutic perspectives in cardiovascular diseases. *Int J Mol Sci*. 2022;23(24):16053. <https://doi.org/10.3390/ijms232416053>
35. Li H, Hu Q, Zhu D, Wu D. The Role of NAD⁺ Metabolism in Cardiovascular Diseases: Mechanisms and Prospects. *Am J Cardiovasc Drugs*. 2025;25(3):307-27. <https://doi.org/10.1007/s40256-024-00711-y>
36. Mladenov M, Lubomirov L, Grisk O, Avtanski D, Mitrokhin V, Sazdova I, et al. Oxidative stress, reductive stress and antioxidants in vascular pathogenesis and aging. *Antioxidants*. 2023;12(5):1126. <https://doi.org/10.3390/antiox12051126>
37. Memon SG, Shaikh P, Shahani MY, Bano U, Rani S, Memon S. Possible protection against cisplatin induced behavioral changes by dietary antioxidants in adult albino mice. *Prof Med J*. 2020;27(6):1217–23. <https://doi.org/10.29309/TPMJ/2020.27.06.4162>
38. Salnikova D, Orekhova V, Grechko A, Starodubova A, Bezsonov E, Popkova T, et al. Mitochondrial dysfunction in vascular wall cells and its role in atherosclerosis. *International Int J Mol Sci*. 2021;22(16):8990. <https://doi.org/10.3390/ijms22168990>
39. Beg MA, Huang M, Vick L, Rao KS, Zhang J, Chen Y. Targeting mitochondrial dynamics and redox regulation in cardiovascular diseases. *Trends Pharmacol Sci*. 2024;45(4):290-303. <https://doi.org/10.1016/j.tips.2024.02.001>
40. Aladağ N, Asoğlu R, Ozdemir M, Asoğlu E, Derin AR, Demir C, et al. Oxidants and antioxidants in myocardial infarction (MI): Investigation of ischemia modified albumin, malondialdehyde, superoxide dismutase and catalase in individuals diagnosed with ST elevated myocardial infarction (STEMI) and non-STEMI (NSTEMI). *J Med Biochem*. 2021;40(3):286. <https://doi.org/10.5937/jomb0-28879>
41. Yan Q, Liu S, Sun Y, Chen C, Yang S, Lin M, et al. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. *J Transl Med*. 2023;21(1):519. <https://doi.org/10.1186/s12967-023-04361-7>
42. Güler MC, Tanyeli A, Akdemir FNE, Eraslan E, Şebin SÖ, Erdoğan DG, et al. An overview of ischemia–reperfusion injury: review on oxidative stress and inflammatory response. *Eurasian J Med*. 2022;54(Suppl 1):S62. <https://doi.org/10.5152/eurasianjmed.2022.22293>
43. Soni SK, Basu P, Singaravel M, Sharma R, Pandi-Perumal SR, Cardinali DP, et al. Sirtuins and the circadian clock interplay in cardioprotection: focus on sirtuin 1. *Cell Mol Life Sci*. 2021;78(6):2503-15. <https://doi.org/10.1007/s00018-020-03713-6>
44. Karakayali M, Ögün M, Artaç İ, Omar T, İliş D, Arslan A, et al. Inducible nitric oxide synthase (iNOS) is a potential marker of myocardial infarction with Non-obstructive coronary artery disease (MINOCA). *Bağcılar Tıp Bülteni*. 2024;9(3):188-95. <https://doi.org/10.4274/BMB.galenos.2024.2023-12-107>
45. Zhao H, Zhang R, Yan X, Fan K. Superoxide dismutase nanozymes: an emerging star for anti-oxidation. *J Mater Chem*. 2021;9(35):6939-57. <https://doi.org/10.1039/d1tb00720c>

